JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?

Novo Nordisk's stock received a favorable outlook from JPMorgan Chase analyst, who predicted strong sales for the company's Wegovy pill. The anticipation proved accurate, as Novo Nordisk has now sold over eight million prescriptions of the GLP-1 weight-loss pill since its launch. The company's success with Wegovy, which surpassed even the popularity of its Wegovy shot, has been a positive development, but it must be considered in the context of the company's overall business strategy.

Novo Nordisk is transitioning to a high-volume/low-price model, which has led to a decline in operating profits by 9% year-over-year. However, the strong adoption of Wegovy suggests that this strategy may be working. Despite competition from Eli Lilly and other potential entrants, Novo Nordisk's stock yield of 4.4% and attractive valuation metrics make it an appealing option for income and value investors.